Annexon, Inc. (NASDAQ:ANNX) completed enrollment of 659 patients in Phase 3 ARCHER II for vonaprument, with topline results due Q4 2026 and Phase 2 baseline traits to be presented at ASRS 2026, while the company granted inducement options to two non‑executive hires in July 2026.
Previous Week Recap
- Annexon ARCHER II Enrollment Completed: Annexon: Phase 3 ARCHER II for vonaprument (C1q inhibitor) completed enrollment at 659 patients in July 2025; topline results expected Q4 2026. ASRS 2026 oral presentation on Phase 2 baseline traits.
- Annexon Grants Inducement Options: Annexon (ANNX) granted 335,000 inducement options to two non‑executive hires, $6.50 strike, 10‑year term, four‑year vesting (25% after 1 year, then monthly), approved July 12, 2026.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.